Protocols for trans-arterial treatments of HCC generally result in a characteristic self-limiting syndrome following embolization, which is described in 40 to 100% of patients, with abdominal pain, ileus, swinging fever, nausea, vomiting and increased serum liver enzymes (AST > 40 mg/dl; ALT > 40 mg/dl) and total bilirubine > 1.1 mg/dl, occurring hours to days after the procedure. The gene discussed is GPT; the disease is hepatocellular carcinoma.